Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Multicenter study of over 1000 females with breast cancer, Read More

2026-04-06T09:27:36-04:00March 31st, 2026|Press Releases|

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More

2026-03-11T15:42:05-04:00January 20th, 2026|Press Releases|

Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium

Four additional poster presentations from the ongoing real-world FLEX Read More

2025-11-24T16:36:40-05:00November 25th, 2025|Press Releases|

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, Read More

2025-08-22T16:35:25-04:00August 12th, 2025|Press Releases|

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting

FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More

2025-06-18T14:05:14-04:00May 27th, 2025|Press Releases|
Go to Top